Other equities research analysts have also recently issued reports about the company. Goldman Sachs Group Inc. reiterated a buy rating and issued a $135.00 price objective on shares of Bluebird Bio in a report on Thursday, August 18th. Zacks Investment Research raised shares of Bluebird Bio from a sell rating to a hold rating in a research note on Monday, August 8th. BTIG Research reissued a buy rating and issued a $72.00 target price on shares of Bluebird Bio in a research note on Wednesday, June 29th. Jefferies Group reissued a positive rating and issued a $80.00 target price on shares of Bluebird Bio in a research note on Thursday, July 14th. Finally, Wedbush reissued an outperform rating and issued a $117.00 target price on shares of Bluebird Bio in a research note on Wednesday, August 3rd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Bluebird Bio presently has a consensus rating of Buy and an average price target of $91.60.
Shares of Bluebird Bio (NASDAQ:BLUE) traded down 0.65% on Friday, reaching $56.20. The company had a trading volume of 451,113 shares. The stock’s market capitalization is $2.09 billion. The company’s 50 day moving average price is $63.71 and its 200-day moving average price is $50.93. Bluebird Bio has a 1-year low of $35.37 and a 1-year high of $99.70.
Bluebird Bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The firm earned $1.55 million during the quarter, compared to analyst estimates of $2.01 million. During the same quarter in the previous year, the firm posted ($1.57) earnings per share. The company’s quarterly revenue was down 68.6% on a year-over-year basis. Equities analysts predict that Bluebird Bio will post ($6.19) EPS for the current year.
In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the business’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $67.00, for a total value of $27,872.00. Following the completion of the transaction, the insider now owns 5,891 shares in the company, valued at $394,697. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 3.50% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of the company. First Mercantile Trust Co. purchased a new position in shares of Bluebird Bio during the third quarter worth approximately $129,000. Seven Eight Capital LLC purchased a new position in shares of Bluebird Bio during the first quarter worth approximately $108,000. Quantbot Technologies LP increased its position in shares of Bluebird Bio by 431.3% in the second quarter. Quantbot Technologies LP now owns 2,848 shares of the company’s stock worth $123,000 after buying an additional 2,312 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Bluebird Bio by 110.5% in the third quarter. BNP Paribas Arbitrage SA now owns 3,084 shares of the company’s stock worth $209,000 after buying an additional 1,619 shares during the last quarter. Finally, Amalgamated Bank purchased a new position in shares of Bluebird Bio during the second quarter worth approximately $222,000.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.